Currently out of the existing stock ratings of David Lebowitz, 163 are a BUY (64.17%), 58 are a HOLD (22.83%), 33 are a SELL (12.99%).

David Lebowitz

Work Performance Price Targets & Ratings Chart

Analyst David Lebowitz, currently employed at CITI, carries an average stock price target met ratio of 69.76% that have a potential upside of 36.05% achieved within 217 days.

David Lebowitz’s has documented 456 price targets and ratings displayed on 30 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on IONS, Ionis Pharmaceuticals at 03-Sep-2025.

Wall Street Analyst David Lebowitz

Analyst best performing recommendations are on PLRX (PLIANT THERAPEUTICS ).
The best stock recommendation documented was for PLRX (PLIANT THERAPEUTICS ) at 3/4/2025. The price target of $1.5 was fulfilled within 1 day with a profit of $0.15 (11.11%) receiving and performance score of 111.11.

Average potential price target upside

AKBA Akebia Ther ALNY Alnylam Pharmaceuticals ARQT Arcutis Biotherapeutics  ASND Ascendis Pharma AS BPMC Blueprint Medicines Corp GWPH GW Pharmaceuticals plc IONS Ionis Pharmaceuticals IRWD Ironwood Pharmaceuticals KPTI Karyopharm Therapeutics MGNX MacroGenics RYTM Rhythm Pharmaceuticals SDGR Schrodinger SNDX Syndax Pharmaceuticals ZEAL Zealand Pharma A/S ADR AVRO AVROBIO IMRX Immuneering Corp EPZM Epizyme MIRM Mirum Pharmaceuticals NTLA Intellia Therapeutics PLRX Pliant Therapeutics  NBRV Nabriva Therapeutics AG BMRN Biomarin Pharmaceutical BBIO BridgeBio Pharma COGT Cogent Biosciences PTCT PTC Therapeutics INCY yte EXEL Exelixis CLDX Celldex Therapeutics CYTK Cytokinetics MDGL Madrigal Pharmaceuticals

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 04-Jun-2025

$6

$4.82 (408.47%)

$6

19 days ago
(06-Feb-2026)

0/4 (0%)

$4.61 (331.65%)

Buy Since 29-Nov-2023

$5

$3.82 (323.73%)

$5

2 months 23 days ago
(02-Dec-2025)

1/3 (33.33%)

$3.53 (240.14%)

602

Buy Since 28-Aug-2023

$7.5

$6.32 (535.59%)

$7.5

10 months 21 days ago
(04-Apr-2025)

14/28 (50%)

$5.73 (323.73%)

327

Buy Since 31-May-2023

$4

$2.82 (238.98%)

$2

2 years 8 months 25 days ago
(31-May-2023)

2/12 (16.67%)

$2.96 (284.62%)

753

Buy Since 08-Mar-2021

$1

$-0.18 (-15.25%)

$8

3 years 10 months 24 days ago
(01-Apr-2022)

1/2 (50%)

$0.33 (49.25%)

311

Show more analysts

Please expand the browser size to see the chart

Which stock is David Lebowitz is most bullish on?

Potential upside of $246.81 has been obtained for ALNY (ALNYLAM PHARMACEUTICALS)

Which stock is David Lebowitz is most reserved on?

Potential downside of $0.85 has been obtained for IONS (IONIS PHARMACEUTICALS)

What Year was the first public recommendation made by David Lebowitz?

On 2016

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?